Alumis
Manufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
280 E Grand Ave, South San Francisco, Ca...Phone Number
(650) 231-6625Website
www.alumis.comRevenue
$24.1 MillionStock Symbol
ALMSIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
4
1
1
1
1
About Alumis
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.Explore more
Alumis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alumis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Alumis is spiking on competitors!
Product Launch: Get notified when Alumis launches new products
Website visits: Recent activity has been detected on your website
Check if Alumis has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Alumis has new funding data
Congratulate Masked Content for being promoted to Masked Content at Alumis
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Alumis recently announced quarterly report
Alumis, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Alumis had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Alumis as Masked Content
Find more new buyers
Compare Similar Companies to Alumis
Compare insights from companies similar to Alumis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Alumis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alumis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alumis.
Alumis financials insights
Gather financial insights about Alumis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series C
$259M
Stock Offering
$250M
Alumis Tech Stack
A closer look at the technologies used by Alumis
Most Recent Scoops
Person-Based
Medical Research
Open Position
Open Position
Open Position
Open Position
Alumis News & Media
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms –
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alumis
Sign Up For FreeTo access detailed company insights
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-pe... Read More
